RecruitingNCT05700149
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Studying Marginal zone lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Principal Investigator
- Davide Rossi, MDOncology Institute of Southern Switzerland and Institute of Oncology Research
- Enrollment
- 300 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- University of Miami, Miami, Florida, United States
- Weill Cornell Medical, New York, New York, United States
- Hematology Center after Prof. Yeolyan, Yerevan, Armenia
- University Hospital Centre Zagreb, Zagreb, Croatia
- AO SS Antonio e Biagio e C. Arrigo, Alessandria, AL, Italy
- Istituto Tumori "Giovanni Paolo II" I.R.C.C.S., Bari, BA, Italy
- ASST Papa Giovanni XXIII, Bergamo, BG, Italy
- ASST degli Spedali Civili di Brescia, Brescia, BS, Italy
- AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto, Catania, CT, Italy
- Azienda Ospedaliero Universitaria di Ferrara, Cona, FE, Italy
- Azienda Ospedaliera Universitaria Careggi, Florence, FI, Italy
- Azienda Ospedaliera Papardo, Messina, ME, Italy
- IRCCS Ospedale San Raffaele, Milan, MI, Italy
- IEO Istituto Europeo di Oncologia, Milan, MI, Italy
- ASST Grande Ospedale Metropolitano Niguarda, Milan, MI, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05700149 on ClinicalTrials.gov